NCT03349723View on ClinicalTrials.gov

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 23, 2017

Primary Completion Date

March 5, 2018

Study Completion Date

March 5, 2018

Conditions
Healthy
Interventions
DRUG

BI 1265162

Single rising dose groups

DRUG

Placebo

Single rising dose groups

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03349723 - This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men | Biotech Hunter | Biotech Hunter